Deutsche Bank AG Purchases New Shares in Adaptive Biotechnologies Corporation $ADPT

Posted by Stanley Muller on Aug 25th, 2026

Deutsche Bank AG purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) during the second quarter, HoldingsChannel reports. The fund purchased 237,406 shares of the company’s stock, valued at approximately $5,092,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. 1492 Capital Management LLC bought a new stake in Adaptive Biotechnologies in the 4th quarter valued at about $1,484,000. Jupiter Asset Management Ltd. increased its holdings in shares of Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after purchasing an additional 91,683 shares during the period. Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $65,942,000. Rhenman & Partners Asset Management AB raised its position in shares of Adaptive Biotechnologies by 22.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock valued at $9,825,000 after buying an additional 110,000 shares in the last quarter. Finally, Jennison Associates LLC raised its position in shares of Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after buying an additional 1,363,181 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $25.55 on Tuesday. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of -62.32 and a beta of 2.08. The firm’s 50 day simple moving average is $22.22 and its 200 day simple moving average is $17.39. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same period last year, the business earned ($0.17) earnings per share. The business’s revenue was up 21.5% compared to the same quarter last year. As a group, research analysts expect that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ADPT has been the subject of several recent research reports. TD Cowen boosted their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. lowered their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Piper Sandler lifted their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Guggenheim upped their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

Read Our Latest Analysis on ADPT

Insider Transactions at Adaptive Biotechnologies

In other news, Director Peter M. Neupert sold 124,690 shares of Adaptive Biotechnologies stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.15, for a total value of $3,135,953.50. Following the transaction, the director owned 130,625 shares in the company, valued at approximately $3,285,218.75. This trade represents a 48.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Chad M. Robins sold 278,676 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total value of $6,821,988.48. Following the completion of the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at approximately $53,379,080.64. The trade was a 11.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,062,325 shares of company stock worth $46,659,069. 5.70% of the stock is owned by insiders.

Adaptive Biotechnologies Company Profile

(Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.